Please provide your email address to receive an email when new articles are posted on . In statin-intolerant patients, inflammation risk contributed more to death and CV events than cholesterol risk.

Please provide your email address to receive an email when new articles are posted on . In patients at high cardiovascular risk already taking statin therapy, level of inflammation better predicted ...

Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk markers with NLRP3 ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

New evidence released today from a study of 31,245 patients already taking statin therapy indicates that inflammation may be a more powerful predictor of risk of future cardiovascular events - such as ...

Inflammation plays a central role in the initiation, progression and resolution of cardiovascular events, from the formation of atherosclerotic plaques to the healing phase after myocardial infarction ...

Atherothrombosis is a progressive disease caused by mineral, lipid, and fibrous deposits in arterial walls. This accumulation leads to the narrowing of the arterial lumen. In addition, Hyperlipidaemia ...

Severe airway inflammation impairs the ability of mice to learn when a dangerous situation is no longer a threat, suggesting that the lungs influence emotions and behaviour. This lung-brain connection ...

Modern medicine is largely reactive—treating illness only after symptoms emerge. But a new study from the Research Institute of the McGill University Health Center (The Institute) and McGill ...

Immunoglobulin G4 (IgG4) fights viruses and bacteria. However, sometimes it targets the body itself. "This then leads to inflammation, the healing of which the body is unable to keep under control," ...

A retrospective case series suggested that faricimab (Vabysmo) intravitreal injections may be associated with rare cases of noninfectious intraocular inflammation. Over a 22-month period, 12 eyes from ...